Protocol summary
-
Study aim
-
Determining and comparing the effect of using oral isotretinoin and desloratadine with oral isotretinoin in the treatment of moderate to severe acne vulgaris.
-
Design
-
A clinical trial with a control group, with parallel groups, double-blind, randomized, phase 3, on 70 patients.
-
Settings and conduct
-
The current research is a randomized clinical trial. whose statistical population consists of patients diagnosed with acne vulgaris who referred to the skin clinic of Sinai Hospital in Hamedan in the years 1401 to 1402. Patients who met the conditions for entering the study will be interviewed after completing the consent form and all patient information such as age, gender, acne severity score, number of lesions and type of skin lesions will be recorded in the checklist. Patients will be randomly classified into two treatment groups in such a way that in terms of disease severity, age and gender are equally distributed in both groups. In order to avoid bias in this study, the researcher and the patient do not know the type of drug assigned and the study is conducted in a double-blind manner.
-
Participants/Inclusion and exclusion criteria
-
Criteria for entering the study:
People with moderate to severe acne
Exclusion criteria:
Age less than 18 years, pregnant and lactating women or women who plan to become pregnant in the near future (due to the teratogenicity of isotretinoin), people with systemic diseases
-
Intervention groups
-
the first group (A): treatment with isotretinoin capsule 20 mg once daily after lunch and desloratadine 10 mg tablet at night before going to sleep for 12 weeks.
The second group (B): treatment with isotretinoin capsules 20 mg daily after meals and placebo tablets at night before sleep for 12 weeks.
-
Main outcome variables
-
Number of acne lesions after treatment
General information
-
Reason for update
-
Due to the shortage of Loratadine drug in the pharmaceutical market of the country at beginning of the trial, with the coordination of the Faculty of Medicine and the Ethics Committee, we changed the drug to Desloratadine, which was available , therefore each field that contains the word Loratadine to Desloratadine will be updated.
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20220705055374N1
Registration date:
2022-07-11, 1401/04/20
Registration timing:
prospective
Last update:
2023-12-09, 1402/09/18
Update count:
1
-
Registration date
-
2022-07-11, 1401/04/20
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
-
Expected recruitment start date
-
2022-08-23, 1401/06/01
-
Expected recruitment end date
-
2023-08-23, 1402/06/01
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
Comparative of the effect of oral isotretinoin and desloratadine with oral isotretinoin in the treatment of moderate to severe acne vulgaris patients
-
Public title
-
Comparative of the effect of oral isotretinoin and desloratadine with oral isotretinoin in the treatment of moderate to severe acne vulgaris patients
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Patient with moderate to severe acne
Exclusion criteria:
Age<18 years
Pregnant and lactating female
Systemic disease
Concurrent use of other acne therapies
Other dermatological condition requiring interfering treatment
-
Age
-
From 18 years old
-
Gender
-
Both
-
Phase
-
3
-
Groups that have been masked
-
- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
-
Sample size
-
Target sample size:
70
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
Random allocation rule: The number of samples allocated to each of the studied groups is equal, so that the intervention group includes 35 people and the control group also includes 35 people. 35 balls for the intervention group and 35 balls for the control group are drawn in a container. and then the balls are randomly removed from the container without replacement and the created sequence is recorded.
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
Desloratadine tablets and placebo tablets will be prepared in the same sealed envelopes so that neither the researcher nor the patient will know the type of drug.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2022-06-27, 1401/04/06
-
Ethics committee reference number
-
IR.UMSHA.REC.1401.319
Health conditions studied
1
-
Description of health condition studied
-
Acne vulgaris
-
ICD-10 code
-
L70.0
-
ICD-10 code description
-
Acne vulgaris
Primary outcomes
1
-
Description
-
Number of acne lesions after treatment
-
Timepoint
-
At baseline and at weeks 4, 8 and 12 after treatment
-
Method of measurement
-
Observe and record in the checklist
Intervention groups
1
-
Description
-
Intervention group: Treatment with isotretinoin capsule 20 mg once daily after lunch and desloratadine 10 mg tablet at night before sleep for 12 weeks.
-
Category
-
Treatment - Drugs
2
-
Description
-
Control group: Treatment with isotretinoin capsules 20 mg daily after meals and placebo tablets at night before sleep for 12 weeks.
-
Category
-
Placebo
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Hamedan University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available